相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Luis Teixeira et al.
CLINICAL CANCER RESEARCH (2020)
Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens
Geoffrey M. Lynn et al.
NATURE BIOTECHNOLOGY (2020)
Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies
Michael Lim et al.
PHARMACEUTICS (2020)
A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer
Rana R. McKay et al.
ADVANCES IN THERAPY (2020)
Activity of OSE-2101 in HLA-A2+non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
G. Giaccone et al.
ANNALS OF ONCOLOGY (2020)
Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling
Anthony C. Antonelli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Personalized deep learning of individual immunopeptidomes to identify neoantigens for cancer vaccines
Ngoc Hieu Tran et al.
NATURE MACHINE INTELLIGENCE (2020)
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
James L. Gulley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors
Patrick A. Ott et al.
CANCER DISCOVERY (2019)
A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge
Elizabeth K. Duperret et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma
Tanner M. Johanns et al.
ONCOIMMUNOLOGY (2019)
Turning the corner on therapeutic cancer vaccines
Robert E. Hollingsworth et al.
NPJ VACCINES (2019)
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
Elizabeth A. Mittendorf et al.
CLINICAL CANCER RESEARCH (2019)
Pathogen Molecular Pattern Receptor Agonists: Treating Cancer by Mimicking Infection
Mark Aleynick et al.
CLINICAL CANCER RESEARCH (2019)
VACCINATION OF CANCER PATIENTS WITH DENDRITIC CELLS ELECTROPORATED WITH MRNA ENCODING THE WILMS' TUMOR 1 PROTEIN (WT1): CORRELATION OF CLINICAL EFFECT AND OVERALL SURVIVAL WITH T-CELL RESPONSE
Z. N. Berneman et al.
CYTOTHERAPY (2019)
Cancer Vaccines
Peter J. DeMaria et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer.
Gal Cafri et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Alessandra Lopes et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
Linda Hammerich et al.
NATURE MEDICINE (2019)
Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer
Masahiro Ogasawara et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2019)
A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy
Masahiro Katsuda et al.
TRIALS (2019)
The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
Kalijn F. Bol et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Peptides as cancer vaccines
Marta Calvo Tardon et al.
CURRENT OPINION IN PHARMACOLOGY (2019)
Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines
Shuichi Hanada et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade
Lee P. Richman et al.
CELL SYSTEMS (2019)
A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
Akihiro Tsuboi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study
Erika J. Crosby et al.
CLINICAL CANCER RESEARCH (2019)
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf et al.
NATURE (2019)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin et al.
NATURE (2019)
Deep learning enables de novo peptide sequencing from data-independent-acquisition mass spectrometry
Ngoc Hieu Tran et al.
NATURE METHODS (2019)
Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor
Leyuan Ma et al.
SCIENCE (2019)
Clinical study of a personalized neoantigen cancer vaccine in treating patients with advanced malignant tumor
Yong Fang et al.
CANCER RESEARCH (2019)
Safety and immunogenicity of a personalized neoantigen-Listeria vaccine in cancer patients
J. Randolph Hecht et al.
CANCER RESEARCH (2019)
The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: Association with clinical outcomes
Siwen Hu-Lieskovan et al.
CANCER RESEARCH (2019)
Current challenges for cancer vaccine adjuvant development
William S. Bowen et al.
EXPERT REVIEW OF VACCINES (2018)
Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.
Harm Westdorp et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Dendritic Cell-Based Cancer Vaccines
Patricia M. Santos et al.
JOURNAL OF IMMUNOLOGY (2018)
MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
Brigitte Dreno et al.
LANCET ONCOLOGY (2018)
Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study
Sumiyuki Nishida et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Computational Strategies for Dissecting the High-Dimensional Complexity of Adaptive immune Repertoires
Enkelejda Miho et al.
FRONTIERS IN IMMUNOLOGY (2018)
A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma.
John Frederick De Groot et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer
Heather L. Kinkead et al.
JCI INSIGHT (2018)
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers
Takuya Osada et al.
BREAST CANCER RESEARCH (2018)
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
Peter G. Maslak et al.
BLOOD ADVANCES (2018)
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Lea Lowenfeld et al.
CLINICAL CANCER RESEARCH (2017)
Designer vaccine nanodiscs for personalized cancer immunotherapy
Rui Kuai et al.
NATURE MATERIALS (2017)
Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
Takumi Kumai et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer
Philip W. Kantoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Ugur Sahin et al.
NATURE (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA
Orin Bloch et al.
NEURO-ONCOLOGY (2017)
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
Abhishek D. Garg et al.
TRENDS IN IMMUNOLOGY (2017)
An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy
Srinivasa Reddy Bonam et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Enhancing Immune Responses to Cancer Vaccines Using Multi-Site Injections
Robert C. Mould et al.
SCIENTIFIC REPORTS (2017)
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
Marjorie G. Zauderer et al.
CLINICAL CANCER RESEARCH (2017)
Initial phase 1 study of WT2725 dosing emulsion in patients with advanced malignancies.
Siqing Fu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
Yasunori Ueda et al.
CANCER SCIENCE (2017)
Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases
Mark B. Faries et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Cancer immunotherapy: moving forward with peptide T cell vaccines
Takumi Kumai et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Peptide vaccines in cancer - old concept revisited
Takumi Kumai et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer et al.
CELL (2017)
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
Gerty Schreibelt et al.
CLINICAL CANCER RESEARCH (2016)
Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication
Omar A. Ali et al.
CANCER IMMUNOLOGY RESEARCH (2016)
The development and use of the E75 (HER2 369-377) peptide vaccine
Guy T. Clifton et al.
FUTURE ONCOLOGY (2016)
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Johan F. Vansteenkiste et al.
LANCET ONCOLOGY (2016)
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Lena M. Kranz et al.
NATURE (2016)
The Human Vaccines Project: A roadmap for cancer vaccine development
Pedro Romero et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer Role for Immune Monitoring
Jashodeep Datta et al.
JAMA ONCOLOGY (2016)
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses
P. Mitchell et al.
ANNALS OF ONCOLOGY (2015)
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study
Hiroki Yamaue et al.
CANCER SCIENCE (2015)
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
G. Giaccone et al.
EUROPEAN JOURNAL OF CANCER (2015)
Therapeutic cancer vaccines
Cornelis J. M. Melief et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Tumor neoantigens: building a framework for personalized cancer immunotherapy
Matthew M. Gubin et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)
David H. Lawson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Cornelia L. Trimble et al.
LANCET (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Beatriz M. Carreno et al.
SCIENCE (2015)
Cancer vaccines
Lisa H. Butterfield
BMJ-BRITISH MEDICAL JOURNAL (2015)
Cancer vaccines
Lisa H. Butterfield
BMJ-BRITISH MEDICAL JOURNAL (2015)
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Kevin C. Soares et al.
JOURNAL OF IMMUNOTHERAPY (2014)
Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma
Ronald Levy et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Charles Butts et al.
LANCET ONCOLOGY (2014)
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton et al.
LANCET ONCOLOGY (2014)
Antigen-specific vaccines for cancer treatment
Maria Tagliamonte et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
Hye-Jung Kim et al.
CANCER IMMUNOLOGY RESEARCH (2014)
BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses
Hyun-Il Cho et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
Jurjen Tel et al.
CANCER RESEARCH (2013)
Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100
Kai Naumann et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation
Rodney A. Rosalia et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial
Alexander M. M. Eggermont et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study
Paul Sabbatini et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Xenogeneic Human p53 DNA Vaccination by Electroporation Breaks Immune Tolerance to Control Murine Tumors Expressing Mouse p53
Ruey-Shyang Soong et al.
PLOS ONE (2013)
Clinical evaluation of therapeutic cancer vaccines
Chizuru Ogi et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma
Robert Suriano et al.
MOLECULAR AND CLINICAL ONCOLOGY (2013)
Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines
Ravi A. Madan et al.
SEMINARS IN ONCOLOGY (2012)
Cross-presentation by dendritic cells
Olivier P. Joffre et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor
Deborah A. Grosenbaugh et al.
AMERICAN JOURNAL OF VETERINARY RESEARCH (2011)
Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma
Stephen J. Schuster et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review
Benqiang Rao et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
David Miles et al.
ONCOLOGIST (2011)
Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine
Xianming Huang et al.
VACCINE (2011)
Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
Howard L. Kaufman et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma
Bryan D. Choi et al.
BRAIN PATHOLOGY (2009)
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
Martin A. Cheever et al.
CLINICAL CANCER RESEARCH (2009)
Long-lasting cross-presentation of tumor antigen in human DC
Florence Faure et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2009)
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
Arnold Freedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation
Martijn S. Bijker et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2008)
Allovectin-7 therapy in metastatic melanoma
Agop Y. Bedikian et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 study group
Alessandro Testori et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
An adjuvant autologous therapeutic vaccine (HSPPC-96 vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentrel, open-label, randomised phase III trial
Christopher Wood et al.
LANCET (2008)
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines
Cornelis J. M. Melief et al.
NATURE REVIEWS CANCER (2008)
CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity
Martijn S. Bijker et al.
JOURNAL OF IMMUNOLOGY (2007)
Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models
Xinmei Zhu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma:: a randomized phase III trial of the DC study group of the DeCOG
D Schadendorf et al.
ANNALS OF ONCOLOGY (2006)
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-0897113; Silva Study)
G Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dendritic cells constitutively present self antigens in their immature state in vivo and regulate antigen presentation by controlling the rates of MHC class II synthesis and endocytosis
NS Wilson et al.
BLOOD (2004)
DNA vaccines - back in the saddle again?
K Powell
NATURE BIOTECHNOLOGY (2004)
Cargo from tumor-expressed albumin inhibits T-Cell activation and responses
MW Graner et al.
CANCER RESEARCH (2004)
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
BL Liu et al.
GENE THERAPY (2003)
Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial
P Hersey et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides
S Zwaveling et al.
JOURNAL OF IMMUNOLOGY (2002)
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group
VK Sondak et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801
JM Kirkwood et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor
M Toda et al.
MOLECULAR THERAPY (2000)
分享论文
